Adequate treatment strategies do not exist for retinal laser injuries. To gain a better understanding of available treatments, data form a variety of human laser accident cases and relevant experimental work was evaluated. Most laser eye injury cases are not attended by an ophthalmologist for several hours to days after injury and most patients are not treated.Of the few cases receiving treatment; only the FDA approved glucocortocoids are available for use. Their use, however, is still controversial. Experimental animal work during the acute phase of injury indicates that productive efforts have targeted neuroprotection, inflammation, ischemia- reperfusion, and lipid peroxidation. Late stage issues for treatment are scarring, retinal hole persistence and expansion, and traction. In summary, treatments for acute and late phase injury are currently inadequate. Preserving existing neural elements should be the top priority in these injuries. We recommend that relevant treatments begin immediately after injury. Other approaches are necessary to target early and late phase secondary damage events that are entrenched.